Assessment of vitamin D effect in compare with placebo in hemodialysis patients

Assessment of vitamin D effect on oxidative stress products level in compare with placebo among hemodialysis patients, (A double blind randomized clinical trial)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181001041190N1

Enrollment

Registered

2019-05-25

Start date

2018-12-31

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease. Diseases of the genitourinary system

Interventions

Intervention 1: Treatment group:Taking vitamin D tablets, 50000 units pill, 4 doses, each two week. Intervention 2: Control group:Taking placebo, 4 doses, each two week.

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Conscious consent, Inclination to participate in the study, A definite diagnosis of chronic renal disease ESRD by renal specialist, at least 6 months past from diagnosis, no mental or physical illness (such as heart disease, severe depression, speech impairment or hearing loss), Non-use to use other complementary therapies, having minimum age 18 and maximum 60 years

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Oxidative stress products such as CAT, SOD, GPx, MDA, PMNs. Timepoint: Before intervention, After intervention. Method of measurement: Biochemical methods.	—

Secondary

Measure	Time frame
Increased levels of antioxidant indices. Timepoint: Before and after intervention. Method of measurement: laboratory kit and biochemical methods.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLeila Malekmakan

Shiraz University of Medical Sciences

malekl@sums.ac.ir+98 71 3235 7282

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026